Services on Demand
Journal
Article
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Similars in
SciELO
Share
Permalink
Revista mexicana de pediatría
Print version ISSN 0035-0052
Abstract
GONZALEZ-GARCIA, Sofía Saraí; CORREA-GONZALEZ, Lourdes Cecilia and GARCIA-ORTIZ, José Elías. Evolution of a patient with type II mucopolysaccharidosis who started treatment with idursulfase at three years of age. Rev. mex. pediatr. [online]. 2021, vol.88, n.6, pp.233-238. Epub Aug 15, 2022. ISSN 0035-0052. https://doi.org/10.35366/105425.
Introduction:
Mucopolysaccharidosis type II (MPS II) or Hunter syndrome is a lysosomal disease caused by deficiency of the enzyme iduronate-2-sulfatase, responsible for the degradation of glycosaminoglycans.
Case presentation:
Male patient diagnosed with MPS II at three years of age. The clinical picture included coarse facial features, splenomegaly, limited joint mobility, recurrent airway infections, and psychomotor retardation. Treatment with idursulfase was started and, after 24 months, his growth and joint mobility have improved; in addition, the volume of the spleen decreased, and he has not presented respiratory infections, but the neurological disorders persist.
Conclusions:
Currently, the availability of idursulfase, as enzyme replacement therapy, has improved the prognosis of MPS II patients.
Keywords : Mucopolysaccharidosis II; Hunter syndrome; iduronate 2 sulfatase; enzyme replacement therapy.
